IRVINE, Calif., Oct. 31, 2012 /PRNewswire/ -- Kennedy Health
System, encompassing three acute care New
Jersey hospitals on the cutting edge of new technology and
medical procedures, today renewed the health system's long-standing
contract and commitment to Masimo SET® as its pulse
oximetry standard-of-care. Kennedy Health System signed another
five-year contract with Masimo for SET® pulse oximetry
and added rainbow® Pulse CO-Oximetry for advanced,
noninvasive patient monitoring.
Kennedy Health System standardized on Masimo SET®
pulse oximetry technology for Measure-Through Motion and Low
Perfusion SpO2, pulse rate, and perfusion index
measurements more than 10 years ago. Masimo SET®
virtually eliminates false alarms1 and increases a
clinician's ability to detect life-threatening events.2
More than 100 independent clinical studies have confirmed that
Masimo SET® technology allows clinicians to accurately
monitor blood oxygen saturation in the most challenging conditions
– establishing the technology as an industry-leading pulse oximetry
that substantially contributes to improved patient outcomes.
Today, the health system is expanding its relationship with
Masimo and deploying two new Masimo rainbow®
SET® Pulse CO-Oximetry measurements: noninvasive total
hemoglobin (SpHb®) and Pleth Variability Index
(PVI®). Masimo SpHb enables clinicians to measure
hemoglobin without a painful needle stick or time-consuming blood
lab analysis,3 while PVI helps clinicians to
noninvasively and continuously assess the fluid status of patients
without invasive procedures.4
Masimo rainbow® SET® technology has been
shown to have the highest pulse oximetry specificity (lowest rate
of false alarms) and sensitivity (highest true alarm
detection),2 as well as noninvasive patient monitoring
solutions that allow clinicians to measure multiple blood
constituents – including: oxygen content (SpOC™), carboxyhemoglobin
(SpCO®), methemoglobin (SpMet®), acoustic
respiration rate (RRa™), and perfusion index (PI) in addition to
the Measure-Through Motion and Low Perfusion performance of Masimo
SET® oxyhemoglobin (SpO2), and pulse rate
(PR).
(1) Shah N, Ragaswamy HB, Govindugari K, Estanol L "Performance
of Three New-Generation Pulse Oximeters during Motion and Low
Perfusion in Volunteers".J Clin Anesth. 2012
Aug;24(5):385-91.
(2) Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike,
George T. "Impact of Pulse Oximetry Surveillance on Rescue Events
and Intensive Care Unit Transfers: A Before-and-After Concurrence
Study." Anesthesiology, February
2010, Vol. 112, Issue 2. Available online here.
(3) Frasca D., Dahyot-Fizelier C., Catherine K., Levrat Q., Debaene
B., Mimoz O. "Accuracy of a Continuous Noninvasive Hemoglobin
Monitor in Intensive Care Unit Patients." Crit Care Med.
2011 Oct;39(10):2277-82. Available online here.
(4) Cannesson M., Desebbe O., Rosamel P., Delannoy B., Robin J.,
Bastien O., Lehot J.J. "Pleth Variability Index to Monitor the
Respiratory Variations in the Pulse Oximeter Plethysmographic
Waveform Amplitude and Predict Fluid Responsiveness in the
Operating Theatre."Br J Anaesth. 2008 Aug;101(2):200-6.
Available online here.
About Kennedy Health System
The Kennedy Health System
is an integrated healthcare delivery system providing a full
continuum of healthcare services, ranging from acute-care hospitals
to a broad spectrum of outpatient and wellness programs. A
multi-site healthcare provider, Kennedy serves the residents of
Camden, Burlington and Gloucester counties. Our mission - to enhance
the health status of the communities it serves - is further
expanded through our educational commitment and affiliation with
the University of Medicine and Dentistry of
New Jersey. Kennedy provides the largest non-public
physician training program in the state of New Jersey. Kennedy Health System has three
hospital campuses in Southern New
Jersey: Cherry Hill,
Stratford and Washington Township. Please visit
www.kennedyhealth.org.
About Masimo
Masimo (NASDAQ: MASI) is the global
leader in innovative noninvasive monitoring technologies that
significantly improve patient care—helping solve "unsolvable"
problems. In 1995, the company debuted Measure-Through Motion and
Low Perfusion pulse oximetry, known as Masimo SET®,
which virtually eliminated false alarms and increased pulse
oximetry's ability to detect life-threatening events. More than 100
independent and objective studies have shown that Masimo
SET® outperforms other pulse oximetry technologies, even
under the most challenging clinical conditions, including patient
motion and low peripheral perfusion. In 2005, Masimo introduced
rainbow SET® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously required invasive procedures, including total hemoglobin
(SpHb®), oxygen content (SpOCTM),
carboxyhemoglobin (SpCO®), methemoglobin
(SpMet®), and Pleth Variability Index (PVI®),
in addition to SpO2, pulse rate, and perfusion index
(PI). In 2008, Masimo introduced Patient SafetyNet™, a remote
monitoring and wireless clinician notification system designed to
help hospitals avoid preventable deaths and injuries associated
with failure to rescue events. In 2009, Masimo introduced
rainbow® Acoustic MonitoringTM, the
first-ever noninvasive and continuous monitoring of acoustic
respiration rate (RRa™). Masimo's rainbow®
SET® technology platform offers a breakthrough in
patient safety by helping clinicians detect life-threatening
conditions and helping guide treatment options. In 2010, Masimo
acquired SEDLine®, a pioneer in the development of
innovative brain function monitoring technology and devices. In
2012, Masimo acquired assets of Spire Semiconductor, LLC, maker of
advanced light emitting diode (LED) and other advanced
component-level technologies; and acquired PHASEIN AB, a developer
and manufacturer of ultra-compact mainstream and sidestream
capnography, multigas analyzers, and handheld capnometry solutions.
Masimo SET® and Masimo rainbow®
SET® technologies also can be found in over 100
multiparameter patient monitors from over 50 medical device
manufacturers around the world. Founded in 1989, Masimo has the
mission of "Improving Patient Outcome and Reducing Cost of Care …
by Taking Noninvasive Monitoring to New Sites and
Applications®." Additional information about Masimo and
its products may be found at www.masimo.com.
Forward-Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, in connection with the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based on
current expectations about future events affecting us and are
subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause
our actual results to differ materially and adversely from those
expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including: total hemoglobin (SpHb), PVI, and acoustic
respiration rate (RRa™) contribute to positive clinical outcomes
and patient safety; risks related to our belief that Masimo
noninvasive medical breakthroughs provide cost-effective solutions
with comparable accuracy and unique advantages, including:
immediate and continuous results that enable earlier treatment
without causing invasive trauma in all patients and in every
clinical situation; as well as other factors discussed in the "Risk
Factors" section of our most recent reports filed with the
Securities and Exchange Commission ("SEC"), which may be
obtained for free at the SEC's website at www.sec.gov. Although we
believe that the expectations reflected in our forward-looking
statements are reasonable, we do not know whether our expectations
will prove correct. All forward-looking statements included in this
press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of today's date. We do not undertake any obligation to
update, amend or clarify these statements or the "Risk Factors"
contained in our most recent reports filed with the SEC, whether as
a result of new information, future events or otherwise, except as
may be required under the applicable securities laws.
Media Contacts:
Mike Drummond
Masimo Corporation
Phone: (949) 297-7434
Email: mdrummond@masimo.com
Masimo, SET, Signal Extraction Technology, Improving Patient
Outcome and Reducing Cost of Care... by Taking Noninvasive
Monitoring to New Sites and Applications, rainbow, SpHb, SpOC,
SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7,
Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter,
Adaptive Threshold Alarm, and SEDLine are trademarks or registered
trademarks of Masimo Corporation. The use of the trademarks Patient
SafetyNet and PSN is under license from University HealthSystem
Consortium.
SOURCE Masimo